Identifying a New Target for Pancreatic Cancer Immunotherapy
Author Information
Author(s): Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y
Primary Institution: Kumamoto University, Kumamoto, Japan
Hypothesis
Can KIF20A be a potential target for anticancer immunotherapy in pancreatic cancer?
Conclusion
KIF20A is a novel promising candidate for anticancer immunotherapeutic target for pancreatic cancers.
Supporting Evidence
- KIF20A was overexpressed in pancreatic cancer tissues but not in normal tissues.
- Three specific peptides from KIF20A were able to induce CTLs in HLA-A2 transgenic mice.
- Human CTLs generated from healthy donors showed cytotoxic responses to cancer cells expressing KIF20A.
Takeaway
Researchers found a new protein called KIF20A that is mostly found in pancreatic cancer cells, which could help create better treatments for this disease.
Methodology
The study used genome-wide cDNA microarray analysis and HLA-A2 transgenic mice to identify CTL epitopes of KIF20A.
Potential Biases
Potential bias in sample selection as tissues were obtained from a single institution.
Limitations
The study primarily focused on HLA-A2 positive individuals, which may limit the applicability of findings to other populations.
Participant Demographics
The study involved 14 patients with pancreatic cancer and healthy donors for PBMCs.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website